N-Acetyl Selank Amidate Reconstitution Calculator

No. Neither the amidate nor its parent peptide Selank has FDA approval. Selank is registered as an anxiolytic pharmaceutical in Russia, with human comparative trials against medazepam and phenazepam; in the US, Selank-class peptides circulate as unregulated dietary supplements/research compounds. N-Acetyl Selank Amidate itself has zero completed human trials (all efficacy data below are extrapolated from Selank (human) and animal studies).

It is Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with an N-terminal acetyl cap and C-terminal amide group. These end-caps block exopeptidases: tracer studies show Selank degrades mainly by sequential terminal cleavage into fragments TKPRP, TKP, RP, and GP. Capping the termini protects against this route, yielding a longer plasma half-life and higher effective bioavailability per milligram (community protocol). Mechanism is otherwise unchanged: Selank is a subtype-selective, concentration-dependent positive allosteric modulator of GABA-A receptors.

Human clinical dosing exists only for intranasal Selank: a 1.5 mg formulation, 2–3 drops 4×/day for 30 days; anxiety trials used 14–30-day intranasal courses. Injectable community dosing for the amidate is 100–400 μg subcutaneous once daily, with split dosing 150–250 μg twice daily, and intranasal amidate 100–200 μg one to two times daily: substantially below the 300 µg/kg i.p. doses used in rodent efficacy models. Route changes the pharmacodynamic profile: in mice, intranasal Selank raised hippocampal NMDA binding (+23%, MK-801 sites), while intraperitoneal raised frontal-cortex GABA-A binding (+38%); cortical NMDA glycine-site effects also diverge by route and strain ]. For cognition, intranasal targets brain delivery quickly; for steady anxiolytic effect, subcutaneous is standard (community protocol).

Fast onset: in healthy humans, resting-state fMRI showed altered amygdala–temporal cortex functional connectivity 5–20 minutes after injection. Clinical anxiolytic effect builds over the first days of a course and persisted about one week after the final dose in a phenazepam-comparison trial. Intranasal Selank reaches brain tissue with intact peptide detectable. The amidate's slower enzymatic degradation extends the action window relative to unmodified Selank (community protocol).

Documented human courses run 14–30 days, with effects outlasting administration (~1 week) and no rebound. No clinical or animal evidence of tolerance, dependence, or withdrawal. The opposite pattern appears: a single 0.3 mg/kg Selank dose reduced naloxone-precipitated morphine withdrawal by 39.6% in rats. Community practice uses 3–4-week cycles for unmodified Selank; the amidate is commonly run 4–6 weeks with an equal off-period (community protocol).

Yes, this combination is deliberately studied and beneficial. In mice, Selank enhanced diazepam/mezapam anxiolysis in the elevated plus maze while blocking their sedative and motor-suppressant effects. In humans, add-on Selank accelerated phenazepam's antidepressant/anxiolytic effect and reduced side effects (sedation, memory impairment, asthenia, orthostatism) versus phenazepam monotherapy. No adverse SSRI interaction is reported; Selank also normalizes serotonin metabolism.

Unknown, no human data. At suprapharmacological 100 μM, Selank reduced GABA⁺ neuron differentiation from mouse embryonic stem cells by 61%, though overall survival/proliferation showed no toxicity. That is insufficient to establish fetal safety. Standard guidance: discontinue if pregnancy is planned or confirmed, and avoid while breastfeeding (community protocol).

Lyophilized amidate is a stable dry powder: glyproline peptides are unusually resistant to degradation and can even survive GI transit. Community handling: store lyophilized vials at −20°C long-term, reconstitute with bacteriostatic water, refrigerate at 2–8°C, and use within 30 days; dry powder tolerates days-to-weeks at room temperature during travel. Legal note: not scheduled federally, but unapproved for human use (unlabeled vials at international borders carry seizure risk ).